Prevalence and risk factors of urethral, penile, and scrotal cancers in Iranian men during 2004-2015: A national cancer registry-based study
Men's Health Journal,
Vol. 6 No. 1 (2022),
1 January 2022
,
Page e7
https://doi.org/10.22037/mhj.v6i1.37861
Abstract
Introduction: Urethral, penile, and scrotal cancers are rare and represent less than 1% of all malignancies. However, they are associated with a high mortality rate and have a significant effect on patients’ quality of life. Penile and urethral cancers comprise 0.6% of all urological cancers. Because of ethnic, geographical, and cultural diversity, risk factors and cancer patterns vary in different communities. We aimed to provide valid information on the prevalence, incidence, and epidemiology of urethral, penile, and scrotal cancers using the National Registry on Cancer of Iran. Methods: This retrospective study of 465 patients included all known cases of urethral, penile, and scrotal cancers from the Department of National Registry on Cancer at the Ministry of Health and Medical Education in Iran during 2004-2015. This study examined the demographic characteristics of patients and discussed the risk factors and possible causes of the above-mentioned cancers. Results: The mean ±SD age at the time of registration was 58.49±20.82 years. The highest and lowest proportions of cases belonged to Tehran/Alborz (14.2%) and Mazandaran (0.65%) provinces, Iran, respectively. Regarding the distribution of records according to a year of registration, these cancers were more prevalent in 2014, and less prevalent in 2004. Conclusion: Urethral, penile, and scrotal cancers were more common in Tehran and Alborz. There was a strong possibility that the prevalence of these cancers is linked to the industrial nature of Tehran and Alborz and the prevalence of human papillomavirus.
- Penile Neoplasms
- Urethral Neoplasms
- Urogenital Neoplasms
How to Cite
References
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA oncology. 2015;1(4):505-27.
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(6):438-51.
Yuvaraja T, Waigankar S, Bakshi G, Prakash G. Genitourinary cancers: Summary of Indian data. South Asian Journal of Cancer. 2016;5(03):122-4.
Spiess PE. Penile, Urethral, and Scrotal Cancer. Urologic Clinics. 2016;43(4):xvii-xviii.
Morrison B. Risk Factors and Prevalence of Penile Cancer. The West Indian Medical Journal. 2014;63(6):559-60.
Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology. 2006;68(6):1164-8.
Wright JL, Morgan TM, Lin DW. Primary scrotal cancer: disease characteristics and increasing incidence. Urology. 2008;72(5):1139-43.
Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. International journal of cancer. 2005;116(4):606-16.
Cai T, Di Vico T, Durante J, Tognarelli A, Bartoletti R. Human papilloma virus and genitourinary cancers: a narrative review. Minerva Urologica e Nefrologica= The Italian Journal of Urology and Nephrology. 2018;70(6):579-87.
Lee CW, Lee ES, Choi H, Koh SK, Lee JM, Chai SE, et al. Incidence estimation of genitourinary cancer in Korea. Journal of Korean Medical Science. 1992;7(2):154-61.
Akbari ME, Hosseini SJ, Rezaee A, Hosseini MM, Rezaee I, Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev. 2008;9(4):549-52.
Merghati-Khoei ES, Rezaei Z, Shojaei-Zadeh D, Azadi NA, Rimaz S, Bayat A, et al. Sexual risk behaviors and condom use barriers in Iranian men with substance use disorders. Addiction & health. 2017;9(1):40.
Yousefzadeh A, Mostafavizadeh SM, Jarollahi A, Raeisi M, Garshasbi M, Siavashvahabi Z, et al. Human papillomavirus (HPV) prevalence and types among women attending regular gynecological visit in Tehran, Iran. Clin Lab. 2014;60(2):267-73.
Ganji Jameshouran MA, Allameh F, Mansouri Tehrani MM, Tasharrofi MA, Javanmard B, Karkan MF, et al. Urological Sarcoma Among the Iranian Population; A National Registry-Based Study. International Journal of Cancer Management. 2020;13(12).
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iranian journal of public health. 2018;47(3):309.
Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine. 2018;97(37).
Bleeker M, Heideman D, Snijders P, Horenblas S, Dillner J, Meijer C. Penile cancer: epidemiology, pathogenesis and prevention. World journal of urology. 2009;27(2):141-50.
Kesheh MM, Keyvani H. The prevalence of HPV genotypes in Iranian population: An Update. Iranian journal of pathology. 2019;14(3):197.
Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. Translational Andrology and Urology. 2017;6(5):791.
- Abstract Viewed: 215 times
- pdf Downloaded: 117 times